Malaria drug, tafenoquine, show positive results from two phase III studies
by Press Release from Outbreak News Today on (#2SQRX)
GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) today announced positive results from two phase III studies of tafenoquine, an investigational 8-aminoquinoline, for the prevention of relapse of Plasmodium vivax (P.vivax) malaria. The headline results, presented today at the International Conference on Plasmodium vivax Research (ICPVR) in Manaus, Brazil, show that a single-dose of 300mg ["]
The post Malaria drug, tafenoquine, show positive results from two phase III studies appeared first on Outbreak News Today.